skip to page content

Homology Medicines Announces Publication in Genetic Engineering & Biotechnology News on Dual Gene Therapy and Nuclease-Free Gene Editing Platform for PKU

BEDFORD, Mass., May 4, 2020 – Homology Medicine’s Chief Scientific Officer, Dr. Albert Seymour describes how the Company’s dual gene therapy and gene editing technology platform is being used to develop treatments and potential cures for patients with genetic diseases, such as phenylketonuria (PKU) in Genetic Engineering & Biotechnology News. Homology’s PKU gene therapy candidate HMI-102 is being evaluated in the Phase 1/2 pheNIX clinical trial for adults with PKU. HMI-103, Homology’s gene editing candidate for PKU, is in IND-enabling studies.